Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Niels Dammes, Dan Peer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

89 Scopus citations


Molecular imaging modalities hold great potential as less invasive techniques for diagnosis and management of various diseases. Molecular imaging combines imaging agents with targeting moieties to specifically image diseased sites in the body. Monoclonal antibodies (mAbs) have become increasingly popular as novel therapeutics against a variety of diseases due to their specificity, affinity and serum stability. Because of the same properties, mAbs are also exploited in molecular imaging to target imaging agents such as radionuclides to the cell of interest in vivo. Many studies investigated the use of mAb-targeted imaging for a variety of purposes, for instance to monitor disease progression and to predict response to a specific therapeutic agent. Herein, we highlighted the application of mAb-targeted imaging in three different types of pathologies: autoimmune diseases, oncology and cardiovascular diseases. We also described the potential of molecular imaging strategies in theranostics and precision medicine. Due to the nearly infinite repertoire of mAbs, molecular imaging can change the future of modern medicine by revolutionizing diagnostics and response prediction in practically any disease.

Original languageEnglish
Pages (from-to)938-955
Number of pages18
Issue number2
StatePublished - 2020


FundersFunder number
Lewis Trust for Blood Cancer
Horizon 2020 Framework Programme647410
European Research Council


    • Autoimmune diseases
    • Cardiovascular diseases
    • Molecular imaging
    • Monoclonal antibodies
    • Oncology


    Dive into the research topics of 'Monoclonal antibody-based molecular imaging strategies and theranostic opportunities'. Together they form a unique fingerprint.

    Cite this